linjc16/ctgov huggingface dataset:
Study of Using Long Acting Antihistamine to Treat Opioid Induced Itching

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is determine if long acting antihistamine like cetirizine can help with itching induced by opioid pain medications.

Official Title
-----------------
Effect of Long Acting Antihistamine on Opioid- Induced Pruritus: A Double-blind Placebo Controlled Study

Conditions
-----------------
Pruritus

Intervention / Treatment
-----------------
* Drug: Cetirizine
* Drug: Placebo or sugar pill


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Children age 6-18yrs on opioids who develop pruritus and are willing to participate in the study Exclusion Criteria: Children with history of chronic urticaria Children with other chronic pruritic condition like eczema, contact dermatitis, psoriasis Children with known hypersensitivity to cetirizine/zyrtec Children on H1 antihistamine like diphenhydramine, hydroxyzine, cetirizine, loratadine, fexofenadine, chlorpheniramine within the last 7days prior to randomization Children who have received Ondansetron within 24hrs prior to randomization Children who are on Tricyclic antidepressants Children who are unwilling or unable to swallow the capsule. Children with chronic liver or kidney disease

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Cetirizine<br>zyrtec 10mg, oral, one time | Drug: Cetirizine<br> <br> |
| Placebo Comparator: Sugar pill<br>Placebo, one pill, one time | Drug: Placebo or sugar pill<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Itch Score | Itch score will be used to analyze our primary outcome. The subjects will have an itch score at baseline and compared to itch score at 3hrs post intervention. Itch score is measured on a scale of 1 to 4, with lower scores indicating less itchiness. | Baseline to 3 hours |
Hepatic Artery From Origin to Segmental Branching: a 500 Case CT Study

Study Overview
=================
Brief Summary
-----------------
The origin of the hepatic artery is known to be highly variable, as reported by Michels in 1966 and other authors. This variability has an indisputable impact regarding hepatic, pancreatic and upper gastro-intestinal surgery. As the investigators go deeper into the liver's parenchyma, full-liver and segment IV studies have also found high levels of variability. Only few cadaveric studies have analyzed the entire liver and with limited sample size. The current CT technology allows for an accurate analysis of the arterial branching thanks to the 0.625mm voxel. The aim of this CT study is to describe the anatomy of hepatic arterial segmental branching from the origin of the hepatic artery.

Official Title
-----------------
Hepatic Artery From Origin to Segmental Branching: a 500 Case CT Study

Conditions
-----------------
Hepatic Artery

Intervention / Treatment
-----------------
* Other: Non intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients undergoing CT with arterial abdominal imaging Exclusion Criteria: imaging with radiological artefact (movement, biliary prothesis,..) hepatic resection (except small non anatomic resections)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients<br> | Other: Non intervention<br>* Non intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Anatomic description of the hepatic artery | Analysis of 0.625mm voxel CT | November 1rst 2019 to May, 30 2020 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hepatic Artery, Anatomy, MDCT
Vitamin D in Vulnerable Adults (VIVA-VA)

Study Overview
=================
Brief Summary
-----------------
Vitamin D insufficiency is a problem of growing concern, given its prevalence in older persons and the association of low vitamin D with multiple major health problems, including mobility and balance deterioration and falls, cardiovascular disease, diabetes, and certain cancers. Sedentary persons are particularly vulnerable for these health problems and generally not adherent to prescribed physical activity. This study will investigate if treatment with vitamin D will benefit physical performance in male veterans age 65 to 95.

Official Title
-----------------
Vitamin D in Vulnerable Adults

Conditions
-----------------
Frail Elderly, Vitamin d Deficiency

Intervention / Treatment
-----------------
* Dietary Supplement: vitamin D
* Dietary Supplement: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: male veterans 65 to 95 years of age independent sedentary vitamin D insufficiency Exclusion Criteria: hypercalcemia renal failure living in a nursing home

Ages Eligible for Study
-----------------
Minimum Age: 65 Years
Maximum Age: 95 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Placebo Arm<br>placebo capsule | Dietary Supplement: placebo<br>* placebo tablet<br>|
| Experimental: Cholecalciferol 4000 IU<br>cholecalciferol 4000 IU daily | Dietary Supplement: vitamin D<br>* cholecalciferol<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Short Physical Performance Battery Test Score | The short physical performance battery (SPPB) examines 3 areas of lower extremity function: static balance test, gait speed test and getting in and out of a chair test. The total SPPB score is the sum of the scores of the 3 components and can range from 0 to 12, with 0 reflecting severe limitations and 12 minimal or no limitations. The ranges for each subscale are: balance (0-4), gait speed (0-4), sit-to-stand (0-4). In all the subscales, 0 reflects worse outcome and 4 best outcome. | baseline and 9 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
aged, vitamin d deficiency
Arachidonic Acid Metabolism in Carotid Stenosis Plaque in Diabetic Patients

Study Overview
=================
Brief Summary
-----------------
Diabetes is associated with an increased risk of cardiovascular complications, as a reflection of the chronic inflammatory status. Monocytes-macrophages in diabetic subjects present impaired arachidonic acid metabolism. Moreover, atheromatous plaques in diabetic subjects seem to be significantly enriched in 2-AA-LPC (2-arachidonoyl-lysophosphatidylcholine) and are more inflammatory and more likely to rupture than are plaques in non-diabetic subjects. We therefore hypothesize that this vulnerability of atheromatous plaques in diabetic subjects could be explained by impaired 2-AA-LPC metabolism within the plaque.

Official Title
-----------------
Arachidonic Acid Metabolism in Carotid Stenosis Plaque in Diabetic Patients

Conditions
-----------------
Carotid Stenosis

Intervention / Treatment
-----------------
* Procedure: blood samples
* Procedure: recover samples of atheromatous plaque


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who have provided explicit consent Patients older than 18 years Patients about to undergo surgery for carotid stenosis Haemoglobin ≥ 7g/dl at the time the sample is taken Respect the maximum volume of blood taken (treatment + research) in 30 days SPECIFIC TO DIABETICS - Patients with type 1 or 2 diabetes diagnosed more than 6 months earlier Exclusion Criteria: Patients under guardianship Patients without health insurance cover Pregnant or breast-feeding women

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Diabetics<br> | Procedure: blood samples<br>* 3 tubes (5 ml volume) collected during surgery<br>Procedure: recover samples of atheromatous plaque<br>* a carotid sample collected during surgery<br>|
| Non-diabetics<br> | Procedure: blood samples<br>* 3 tubes (5 ml volume) collected during surgery<br>Procedure: recover samples of atheromatous plaque<br>* a carotid sample collected during surgery<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in arachidonic acid metabolism of atheromatous plaques from diabetic versus non-diabetic subjects |  | Baseline |
The Role of Novel Organisms in Acute Endometritis

Study Overview
=================
Brief Summary
-----------------
The goal of this project is to identify the microorganisms present in the endometrial samples obtained from women with or without evidence of endometritis using a combination of culture methods, rRNA sequencing and whole genomic sequencing. The overarching aim of these studies is to identify the etiology of endometritis. The investigators will define the role of fastidious anaerobic microorganisms in the etiology of PID, and assess whether antibiotic treatment regimens used for the treatment of PID have activity against the novel organisms linked with pelvic infections.

Official Title
-----------------
Characterization of Novel Organisms in the Genital Tract of Women With PID and Determination of Their Association With Endometritis.

Conditions
-----------------
Pelvic Inflammatory Disease

Intervention / Treatment
-----------------
* Other: no intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: This is a laboratory research study involving the use of biologic specimens only. Specimens (endometrial biopsy samples) collected from subjects who meet the inclusion criteria for PRO10010159 and PRO10010112 will be utilized for this study. Exclusion Criteria: Specimens (endometrial biopsy samples) that are collected from subjects enrolled in PRO10010159 and PRO10010112 that are insufficient will not be included in this study.

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Endometrial biospy samples<br>The Endometrial Biopsy samples will be provided by women enrolled in the University of Pittsburgh IRB PRO10010112 and PRO10010159 | Other: no intervention<br>* Not Applicable- no intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Identification of Novel Organsims from PRO10010159 | This study will use optimized culture methods which can support the growth of fastidious organisms to describe the microorganisms in endometrial tissue samples obtained from the 200 women enrolled in the cervicitis cohort (PRO10010159, T Cell Response). | 12 months after participant enrollment in PRO10010159 | 
| Identification of Novel Organisms from PRO10010112 | This study will use optimized culture methods which can support the growth of fastidious organisms to describe the microorganisms in endometrial tissue samples obtained from 250 women enrolled in the acute PID study before and after treatment (PRO10010112, Acute PID treatment). | 30 days after participant enrollment in PRO10010112 |
A Study of Nystatin in the Prevention of Fungal Infections of the Mouth in Patients With AIDS or AIDS-Related Syndromes

Study Overview
=================
Brief Summary
-----------------
To determine a safe, effective, and convenient dosing schedule for nystatin pastilles in the prophylaxis of oral candidiasis in patients with AIDS or AIDS related syndromes (group III or IV, CDC classification)

Official Title
-----------------
Nystatin Pastille for the Prophylaxis of Oral Candidiasis in Patients With AIDS or AIDS Related Syndromes

Conditions
-----------------
Candidiasis, Oral, HIV Infections

Intervention / Treatment
-----------------
* Drug: Nystatin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Concurrent Medication: Allowed: Experimental drugs (IND drugs) which are targeted specifically against the AIDS virus or which stimulate the immune system. Systemic or oral antibiotics. Patients must have AIDS or AIDS-related syndromes (HIV infection: Group III or IV, CDC classification) and not have been treated for oral candidiasis during the past year. Patients can be entered into the study who have: Other oral lesions due to Kaposi's sarcoma, herpes zoster, and herpes simplex. A positive or negative oral culture for Candida. Must be able to follow instructions regarding the use of a pastille. Exclusion Criteria Co-existing Condition: Patients with the following are excluded: Oral lesions diagnostic of oral candidiasis or systemic candidiasis. Suspected or proven candidal esophagitis. Patients with the following are excluded: Oral lesions diagnostic of oral candidiasis or systemic candidiasis. Receiving any effective antifungal agent orally or intravenously within 72 hours of study entry. Not expected to survive for at least 6 months. Unable to voluntarily maintain a pastille in the buccal cavity for approximately 20 minutes twice a day. Known hypersensitivity to nystatin. Suspected or proven candidal esophagitis. Prior Medication: Excluded within 72 hours of study entry: Any oral or intravenous antifungal agent.

Ages Eligible for Study
-----------------
Minimum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Nystatin|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Nystatin, AIDS-Related Opportunistic Infections, Acquired Immunodeficiency Syndrome, AIDS-Related Complex, Candidiasis, Oral
Alterations in Serotonergic Functions in Cocaine Addicts - 1

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate alterations in the serotonergic system in cocaine addicts and attempt to dissociate changes secondary to cocaine use from those associated with premorbid characteristics.

Official Title
-----------------
Alterations in Serotonergic Functions in Cocaine Addicts

Conditions
-----------------
Cocaine-Related Disorders

Intervention / Treatment
-----------------
* Drug: M-CPP


Participation Criteria
=================
Eligibility Criteria
-----------------
Please contact site for information.

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: M-CPP|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Side effects |  |  | 
| Neuroendocrine changes |  |  | 
| Psychological changes |  |  | 
| Craving |  |  |
Regaining Bladder Control in Postmenopausal Women With Osteoporosis

Study Overview
=================
Brief Summary
-----------------
Conservative management for urinary incontinence has been shown to improve bladder control. We are conducting a study of the effectiveness of conservative management for urinary incontinence in women who also have osteoporosis. We hope to find that treatment for incontinence improves bladder control and thereby allows women to be more active and reduces their risk of falling and breaking bones.

Official Title
-----------------
Regaining Urinary Continence in Postmenopausal Women With Osteoporosis: A Randomized Controlled Trial.

Conditions
-----------------
Urinary Incontinence

Intervention / Treatment
-----------------
* Behavioral: Physiotherapy for urinary incontinence


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Postmenopausal women osteopenia or osteoporosis and stress urinary incontinence Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 55 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Physiotherapy for urinary incontinence|See Detailed Description.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Incontinent Episodes (baseline and end of treatment (12 weeks) |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Urinary Distress Inventory |  |  | 
| Pelvic Floor Muscle Strength |  |  | 
| Quality of life: Each participant will complete the Incontinence Impact Questionnaire and the SF-36 at the initial and follow up measurement sessions |  |  | 
| Physical Activity (PASE) |  |  | 
| 24 Hour Pad Test |  |  | 
| Voiding Frequency using the bladder diary |  |  | 
| Spinal Curvature with a flexicurve ruler |  |  | 
| Self-Perceived Efficacy |  |  | 
| All at initial and follow up (end) measurement sessions |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Randomized clinical trial, osteoporosis, urinary incontinence, physiotherapy, education
Screening for Latent Tuberculosis in Healthcare Workers With Quantiferon-Gold Assay: A Cost-Effectiveness Analysis

Study Overview
=================
Brief Summary
-----------------
The ministry of health in Israel requires all health-care workers to undergo screening for latent Tuberculosis infection (LTBI) prior to starting work. This is based on the Mantoux skin test, which is notoriously unreliable. In recent years, more specific and sensitive tests based on interferon-gamma secretion to TB antigens have come to market, and most current evidence shows that many mantoux positive persons do not have LTBI. Quantiferon-GOLD is one of these assays. In this prospective study, we will draw blood for the Quantiferon-GOLD assay in parallel to conventional testing, and perform a cost-effectiveness analysis of the cost of the investigation and treatment of LTBI in health-care workers. We hypothesize that in spite of the cost of screening healthcare workers with Quantiferon-GOLD tests, the reduction in need for LTBI treatment and associated costs will render the test cost-effective.

Conditions
-----------------
Latent Tuberculosis Infection

Intervention / Treatment
-----------------
* Procedure: Blood test for Quantiferon-GOLD assay


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Health care worker undergoing screening for LTBI Exclusion Criteria: Previous tuberculosis or treatment for LTBI Immunosuppressed due to drug treatment, HIV, organ transplant Recent TB contacts

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Blood test for Quantiferon-GOLD assay|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Latent tuberculosis infection, Health care workers, Tuberculin skin test, Mantoux skin test, Interferon gamma, Quantiferon, Cost effectiveness